TRION Research GmbH

What TRION Research GmbH does

TRION Research GmbH is an independent biotech research organization founded in 1998 by Dr. Horst Lindhofer and headquartered in Puchheim, near Munich, Germany. The firm provides specialized diagnostic, preclinical, and clinical development services to pharmaceutical and biotechnology companies, as well as academic research institutions, focused on supporting the development of novel immunotherapies — most notably trifunctional bispecific antibodies based on its proprietary Triomab® technology platform. The organization is a strategic partner of TRION Pharma GmbH and operates with a small team (1–10 employees) under founder control, with no disclosed institutional investors.

The company's core technical asset is the Triomab® antibody platform, a trifunctional bispecific antibody architecture used in cancer immunotherapy. TRION Research supported the preclinical and clinical development of all Triomab® family antibodies, including Removab® (catumaxomab), which in 2010 became the first bispecific trifunctional antibody to receive market approval worldwide, as well as Lymphomun® (FBTA05/Bi20) for B-cell lymphoma and the Catuvab device for EpCAM-positive tumor cell removal. Service offerings span liquid biopsy diagnostics (analysis of virus-infected cells and disseminated tumor cells in body fluids), preclinical support (highly sensitive ELISA and FACS assays, in vitro pre-medication testing, tailored immunological assay development), and clinical services (immunomonitoring, trial design, tumor biology analysis, data management, and logistics).

Revenue is generated through a B2B professional services model via direct engagement with pharma/biotech clients and long-term collaborations with academic and industry partners, including Helmholtz-Zentrum München, Charité Berlin, and LINDIS Biotech. Pricing is quote-based and not publicly disclosed, consistent with bespoke contract research engagements. Marketing is conducted primarily through scientific publications, academic and industry collaborations, and a bilingual (German/English) website rather than traditional sales channels. The firm's geographic footprint is concentrated in the Munich/Germany region with no claimed global operations.

Name

TRION Research GmbH

Legal name

TRION Research GmbH

Website

https://trionresearch.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

TRION Research GmbH is an independent German biotech research organization providing specialized diagnostic, preclinical, and clinical development services for novel immunotherapies, with deep expertise in the proprietary Triomab® trifunctional bispecific antibody platform, serving pharmaceutical, biotech, and academic partners.

Ownership category

akta.pro rank

Product category

Biotech Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Predictive Biomarkers for Therapy Selection (response/non-response stratification) (HLAAAMAE)

Keywords

• Immunotherapy development services
• Liquid biopsy diagnostics
• Preclinical assay services
• Clinical immunomonitoring
• Bispecific antibody research

Headquarters

HQ city

Martinsried

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Specialized Diagnostic Services: Liquid Biopsy diagnostics providing analysis of virus-infected cells and detection of disseminated tumor cells in various body fluids for research and clinical purposes.
2. Preclinical Services: Preclinical development support including highly sensitive ELISA and FACS assays, in vitro pre-medication testing, and development of tailored immunological assays.
3. Clinical Development Services: Clinical support services including trial design, immunomonitoring, tumor biology analysis, data management, and logistics solutions for pharmaceutical and biotech partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

TRION Research provides specialized diagnostic, preclinical, and clinical development services that support pharmaceutical and biotech companies developing novel immunotherapies, particularly trifunctional bispecific antibodies. Core services include liquid biopsy diagnostics (analysis of virus-infected cells and disseminated tumor cells in blood, urine, and other body fluids), highly sensitive ELISA and FACS assays, in vitro pre-medication testing, tailored immunological assay development, clinical immunomonitoring, trial design, tumor biology analysis, data management, and clinical logistics. All work is grounded in the company's deep expertise with its proprietary Triomab® antibody platform.

Product overview

TRION Research GmbH is an independent research organization offering specialized diagnostic services and preclinical/clinical development support for novel immunotherapies. The company provides a portfolio of services centered around Liquid Biopsy diagnostics, including analysis of virus-infected cells and detection of disseminated tumor cells. Their preclinical services include highly sensitive ELISA and FACS assays, in vitro pre-medication testing, and development of tailored immunological assays. Clinical services encompass immunomonitoring, trial design, tumor biology analysis, data management, and logistics. The company has supported the development of the Triomab® technology platform, which underlies bispecific/trifunctional antibody candidates including Removab® (Catumaxomab) and Lymphomun® (FBTA05/Bi20), as well as the Catuvab medical device for tumor cell removal.

Differentiator

Problem solved

Functional benefit

Brands

• Triomab®: Technology platform for trifunctional bispecific antibodies used in cancer immunotherapy development.

Products and services

• Liquid Biopsy Diagnostics Analysis of virus-infected cells and detection of disseminated tumor cells in blood, urine, and other body fluids for cancer diagnostics and immunotherapy monitoring. Intended for pharmaceutical and biotech partners and academic researchers developing cancer immunotherapies and related diagnostics.
• Preclinical Services Highly sensitive ELISA and FACS assays, in vitro pre-medication testing, and development of tailored immunological assays supporting preclinical drug development for pharmaceutical and biotech clients.
• Clinical Services Clinical trial support including immunomonitoring, analysis of EBV-infected cells, trial design, tumor biology analysis, data management, and logistics solutions for pharmaceutical and biotech partners.
• Immunomonitoring Assessment of how drug candidates modulate patients' immune systems and correlation of these effects with clinical outcomes during clinical trials, for pharmaceutical and biotech clients running immunotherapy trials.

Quantifiable outcome

• Supported development of Removab®, the first bispecific trifunctional antibody approved worldwide

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Helmholtz-Zentrum MünchencoreStrategic or Co-development PartnerAcademic collaboration with the German Research Center for Environmental Health. The Research Group Prevention and Immunomodulation led by Prof. Dr. Reinhard Zeidler focuses on research relevant to immunotherapy development projects supported by TRION Research.
• Charité BerlincoreStrategic or Co-development PartnerAcademic collaboration with the Department of Pediatrics, Division of Oncology and Hematology led by PD Dr. med. Annette Künkele. Supports pediatric oncology research projects and immunotherapy development.
• LINDIS BiotechcoreStrategic or Co-development PartnerStrategic collaboration for the development of drug candidates based on LINDIS Triomab® technology platform. This is a key strategic partnership for advancing trifunctional antibody therapeutics through preclinical and clinical development.

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Genmab: Denmark-based biotech with proprietary DuoBody®, HexaBody®, and HexElect® bispecific antibody platforms, partnered globally for immuno-oncology development. Highly comparable bispecific antibody engineering and immunotherapy focus.
• Selvita: Polish-listed CRO/CDMO providing integrated drug discovery and preclinical development services with a dedicated biologics offering. Closely comparable business model as a European mid-sized CRO serving biologics/immunotherapy developers.
• Crown Bioscience: JSR Life Sciences-owned preclinical CRO specializing in oncology and immuno-oncology services, including translational biomarker and immune-monitoring offerings. Closely comparable niche oncology services positioning for biopharma R&D.
• Molecular Partners: Swiss-listed developer of DARPin-based multispecific therapeutics for oncology and infectious disease, including MP0310 for tumor immunotherapy. Directly comparable bispecific/multispecific antibody engineering focus and immunology development orientation.
• Pieris Pharmaceuticals: Clinical-stage biotech developing Anticalin®-based multispecific therapeutics for cancer and respiratory disease. Comparable in developing non-Ig scaffold bispecific/multispecific therapeutics, with similar immunotherapy pipeline focus.
• MacroGenics: Clinical-stage biotech developing DART® and TRIDENT® bispecific antibody platforms for cancer immunotherapy. Most direct bispecific antibody platform competitor with shared anti-tumor immunotherapy focus.
• GenScript ProBio: Biologics CDMO and contract research services provider with antibody discovery, bispecific engineering, and cell therapy development capabilities. Comparable biologics services model serving immunotherapy developers, with broader bispecific antibody engineering offerings.

Broad incumbents

• Charles River Laboratories: Global full-service CRO with extensive preclinical, discovery, and safety assessment capabilities including immunology and biologics services. Major incumbent offering the same categories of work (preclinical assays, immunoassays) at much greater scale and geographic reach.
• IQVIA: World's largest clinical CRO and biopharma services firm with immunomonitoring, biomarker, and lab-services capabilities that overlap directly with TRION Research's clinical development and assay offerings.
• Eurofins Scientific: Global laboratory services group offering bioanalytical, immunogenicity, biomarker, and immunoassay services. Comparable ELISA/FACS and immunology assay capabilities, scaled across pharma and academic clients worldwide.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TRION Research GmbH